Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have received a consensus recommendation of “Moderate Buy” from the twenty-five research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $298.61.

Several equities research analysts have recently weighed in on ALNY shares. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Sanford C. Bernstein dropped their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th.

Alnylam Pharmaceuticals Stock Down 1.9 %

Alnylam Pharmaceuticals stock opened at $273.99 on Thursday. The firm has a fifty day moving average price of $249.42 and a two-hundred day moving average price of $260.65. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market cap of $35.34 billion, a price-to-earnings ratio of -104.58 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.15 earnings per share. As a group, analysts forecast that Alnylam Pharmaceuticals will post -2.24 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock worth $20,622,925 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $33,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.